The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients

Summary

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC COVID-19 wards. Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow KHCC SOC.

Timeline

Start

2022-10

Primary completion

2022-11

Completion

2022-12

Outcome

Outcome not reported

Stopped: “the study was terminated as no more COVID cases were treated at the center”

Drugs

Indications